Search Results - Loïck Galland

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

    Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era by Laura Kalfeist, Loïck Galland, Fanny Ledys, François Ghiringhelli, Emeric Limagne, Sylvain Ladoire

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

    Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness by Robby Barnestein, Loïck Galland, Laura Kalfeist, François Ghiringhelli, Sylvain Ladoire, Emeric Limagne

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS

    Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS by Laura Kalfeist, Stacy Petit, Loïck Galland, François Ghiringhelli, Sylvain Ladoire, Emeric Limagne

    Published 2023-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1

    Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1 by Loïck Galland, Anne Laure Le Page, Julie Lecuelle, Frederic Bibeau, Youssef Oulkhouir, Valentin Derangère, Caroline Truntzer, François Ghiringhelli

    Published 2021-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers

    Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers by Elise Ballot, Loïck Galland, Hugo Mananet, Romain Boidot, Laurent Arnould, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Anthony Bergeron, Valentin Derangère, François Ghiringhelli, Caroline Truntzer, Sylvain Ladoire

    Published 2022-11-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing

    Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing by Loïck Galland, Elise Ballot, Hugo Mananet, Romain Boidot, Julie Lecuelle, Juliette Albuisson, Laurent Arnould, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Anthony Bergeron, Valentin Derangère, François Ghiringhelli, Caroline Truntzer, Sylvain Ladoire

    Published 2022-03-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry

    Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Dat... by Sylvain Ladoire, Ariane Mamguem Kamga, Loick Galland, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Mihaelia Ilie, Audrey Hennequin, Clementine Jankowski, Juliette Albuisson, Sophie Nambot, Charles Coutant, Laurent Arnould, Manon Reda, Caroline Truntzer, Sandrine Dabakuyo

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer by Nicolas Roussot, Jean-David Fumet, Emeric Limagne, Marion Thibaudin, Alice Hervieu, Audrey Hennequin, Sylvie Zanetta, Lorraine Dalens, Théo Fourrier, Loick Galland, Pierre Jacob, Aurélie Bertaut, Emilie Rederstorff, Cédric Chevalier, Sarah Ghirardi, Elodie Gilbert, Azzat Khoukaz, Etienne Martin, Constance Nicolet, Magali Quivrin, David Thibouw, Noémie Vulquin, Gilles Truc, Magali Rouffiac, Francois Ghiringhelli, Céline Mirjolet

    Published 2023-11-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: